GlaxoSmithKline S.A.E.

As of September 30, 2016, GlaxoSmithKline S.A.E. carries a market capitalization of 932.02M, placing it among publicly traded companies globally. Its enterprise value stands at 367.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2016, GlaxoSmithKline S.A.E. has 83.51M shares outstanding.

As of September 30, 2016, GlaxoSmithKline S.A.E. trades at a trailing price-to-earnings ratio of 3.46. The price-to-sales ratio is 0.83, and the price-to-book ratio stands at 0.87.

As of September 30, 2016, GlaxoSmithKline S.A.E. trades at an EV/EBITDA multiple of 1.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. GlaxoSmithKline S.A.E. trades at an EV/FCF ratio of 13.14, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 367.09M versus a market cap of 932.02M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2016, GlaxoSmithKline S.A.E. maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2016, GlaxoSmithKline S.A.E. posted a return on equity (ROE) of 28.78, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 26.34 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 28.77, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.72 indicates how many times GlaxoSmithKline S.A.E. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2016, GlaxoSmithKline S.A.E. recorded 53.97M in income tax expense. That works out to an effective tax rate of 16.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 323.62M, leaving 269.61M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, GlaxoSmithKline S.A.E.'s stock has gained approximately 266.24% over the past 52 weeks. The 50-day moving average sits at 338.69, while the 200-day moving average is 152.31.

Over the twelve months ended September 30, 2016, GlaxoSmithKline S.A.E. generated 1.13B in revenue and converted that into 269.61M in net income, yielding earnings per share of 3.23. EBITDA reached 314.09M, while operating income came in at 299.70M.

These figures are as of September 30, 2016. Total book value stands at 1.07B, with working capital of 583.92M providing operational flexibility.

GlaxoSmithKline S.A.E. produced 74.83M in operating cash flow over the twelve months ended September 30, 2016. After subtracting -46.89M in capital expenditures, free cash flow totaled 27.94M - equivalent to 0.33 per share.

Over the twelve months ended September 30, 2016, GlaxoSmithKline S.A.E. posted a gross margin of 44.60, reflecting its pricing power and cost economics. The operating margin of 26.59 and net profit margin of 23.92 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2016. Free cash flow yield stands at 3.00, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

GlaxoSmithKline S.A.E.'s most recent stock split took place on August 1, 2006.

As of September 30, 2016, GlaxoSmithKline S.A.E. has an Altman Z-Score of 2.54, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.